ClinicalTrials.gg
CompletedNCT00530946Updated Jan 28, 2021Results posted

A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin

A Phase 3 interventional study of Amlodipine 2.5mg/Atorvastatin 5mg and Amlodipine 2.5mg/Atorvastatin 10mg in Hypertension and Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 17 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
97th of 186
165 · median 180
Started
2007
with 16 others
Phase 3
69 of 187
2 open now
Registered
47th of 187
by date
Lead sponsor
6 of 187
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 187 studies testing amlodipine in Hypertension, this one is the 97th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 47th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period

03

Conditions studied

  • Hypertension
  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The out-patient with concurrent hypertension and hyper-LDL-cholesterolemia is a male or female >=20 to \<80 years of age at Visit 1.
  • The SBP at Visit 4 (Week -1) and Visit 5 (Week 0) is continuously SBP >=140 mmHg and \<180 mmHg,
  • LDL-C >=140 mg/dL and \<250 mg/dL at Visit 3 (Week -2) and 4 (Week -1).

Exclusion criteria

Exclusion Criteria:

  • Subjects who had experienced the following coronary artery disease within the past 3 months.
  • Myocardial infarction
  • Receiving PCI(percutaneous coronary intervention)or CABG (coronary artery bypass grafting)
  • Any valvular disease
  • Subjects with a history of cerebrovascular diseases such as stroke or within the past 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Active comparator
    CI-1038 2.5mg/5mg

    Drug: Amlodipine 2.5mg/Atorvastatin 5mg

  • Active comparator
    CI-1038 2.5mg/10mg

    Drug: Amlodipine 2.5mg/Atorvastatin 10mg

  • Active comparator
    CI-1038 5mg/5mg

    Drug: Amlodipine 5mg/Atorvastatin 5mg

  • Active comparator
    CI-1038 5mg/10mg

    Drug: Amlodipine 5mg/Atorvastatin 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Systolic Blood Pressure

    Value at Week 8 minus value at baseline

    Time frame: 8 weeks

  2. Percent Change in Low Density Lipoprotein-Cholesterol

    Percent of "value at Week 8 minus value at baseline" over value at baseline

    Time frame: 8 weeks

Secondary outcomes

  1. Change in Systolic Blood Pressure From Baseline to Each Observation Point

    Value at Week 2, Week 4, or Week 8 minus value at baseline

    Time frame: 2 weeks, 4 weeks, and 8 weeks

  2. Change in Diastolic Blood Pressure From Baseline to Each Observation Point

    Value at Week 2, Week 4, or Week 8 minus value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  3. Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point

    Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  4. Percent Change in Total Cholesterol From Baseline to Each Observation Point

    Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  5. Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point

    Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  6. Percent Change in Triglycerides From Baseline to Each Observation Point

    Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  7. Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point

    Value at Week 2, Week 4, or Week 8 minus value at baseline

    Time frame: 2 weeks, 4 weeks, and 8 weeks

  8. Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point

    Value at Week 2, Week 4, or Week 8 minus value at baseline

    Time frame: 2 weeks, 4 weeks , and 8 weeks

  9. Change in Apolipoprotein B From Baseline to Each Observation Point

    Value at Week 2, Week 4, or Week 8 minus value at baseline

    Time frame: 2 weeks, 4 weeks, and 8 weeks

07

Results

Posted Apr 13, 2009

Participant flow

Twenty (20) centers in Japan

Participant flow — Overall Study
MilestoneCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Started43414140
Completed41394038
Not completed2212
Withdrew: Adverse event1211
Withdrew: Protocol violation0001
Withdrew: Noncompliance1000

Outcome measures

PrimaryChange in Systolic Blood Pressure

Value at Week 8 minus value at baseline

Time frame:
8 weeks
Reported as:
Least squares mean · mm Hg
Change in Systolic Blood Pressure
mm HgCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Change in Systolic Blood Pressure-16.6 ± 1.65-15.9 ± 1.69-21.8 ± 1.69-18.9 ± 1.71
PrimaryPercent Change in Low Density Lipoprotein-Cholesterol

Percent of "value at Week 8 minus value at baseline" over value at baseline

Time frame:
8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change in Low Density Lipoprotein-Cholesterol
Percent ChangeCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Percent Change in Low Density Lipoprotein-Cholesterol-37.2 ± 1.49-42.5 ± 1.52-34.3 ± 1.52-40.6 ± 1.54
SecondaryChange in Systolic Blood Pressure From Baseline to Each Observation Point

Value at Week 2, Week 4, or Week 8 minus value at baseline

Time frame:
2 weeks, 4 weeks, and 8 weeks
Reported as:
Mean · mm Hg
Change in Systolic Blood Pressure From Baseline to Each Observation Point
mm HgCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-12.8 ± 9.63-13.5 ± 10.18-19.2 ± 10.53-16.0 ± 9.01
Week 4-14.2 ± 10.26-14.6 ± 12.33-20.2 ± 11.08-19.6 ± 11.03
Week 8-16.8 ± 11.40-15.3 ± 11.59-21.3 ± 10.07-18.7 ± 11.24
SecondaryChange in Diastolic Blood Pressure From Baseline to Each Observation Point

Value at Week 2, Week 4, or Week 8 minus value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · mm Hg
Change in Diastolic Blood Pressure From Baseline to Each Observation Point
mm HgCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-4.9 ± 6.23-6.0 ± 6.05-8.1 ± 6.24-8.2 ± 6.38
Week 4-5.3 ± 4.96-8.2 ± 7.13-9.4 ± 6.19-9.2 ± 6.62
Week 8-7.7 ± 6.34-8.7 ± 8.06-12.0 ± 6.31-9.9 ± 6.57
SecondaryPercent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point

Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · Percent Change
Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
Percent ChangeCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-34.8 ± 9.11-42.5 ± 11.00-32.8 ± 9.15-40.2 ± 13.52
Week 4-37.4 ± 7.67-43.8 ± 9.30-35.0 ± 9.19-41.8 ± 9.53
Week 8-37.6 ± 7.80-42.9 ± 10.28-34.2 ± 9.22-40.8 ± 11.28
SecondaryPercent Change in Total Cholesterol From Baseline to Each Observation Point

Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · Percent Change
Percent Change in Total Cholesterol From Baseline to Each Observation Point
Percent ChangeCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-24.2 ± 6.86-30.5 ± 8.44-23.0 ± 7.22-28.3 ± 10.04
Week 4-26.6 ± 6.36-31.5 ± 7.08-24.7 ± 7.64-28.6 ± 7.44
Week 8-26.1 ± 6.01-30.0 ± 8.43-23.4 ± 7.78-28.2 ± 8.73
SecondaryPercent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point

Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · Percent Change
Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
Percent ChangeCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 27.7 ± 12.118.3 ± 10.706.6 ± 9.129.9 ± 10.32
Week 47.2 ± 8.167.9 ± 13.039.3 ± 13.2411.9 ± 13.28
Week 87.2 ± 10.867.5 ± 13.279.7 ± 10.5910.8 ± 9.66
SecondaryPercent Change in Triglycerides From Baseline to Each Observation Point

Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · Percent Change
Percent Change in Triglycerides From Baseline to Each Observation Point
Percent ChangeCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-15.1 ± 33.82-27.4 ± 22.48-16.2 ± 20.00-23.9 ± 24.51
Week 4-14.2 ± 25.31-25.7 ± 18.15-15.1 ± 22.42-23.2 ± 28.55
Week 8-14.1 ± 19.72-21.1 ± 21.68-10.8 ± 31.42-24.0 ± 25.15
SecondaryChange in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point

Value at Week 2, Week 4, or Week 8 minus value at baseline

Time frame:
2 weeks, 4 weeks, and 8 weeks
Reported as:
Mean · Ratio
Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point
RatioCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-1.2 ± 0.58-1.4 ± 0.42-1.1 ± 0.49-1.3 ± 0.53
Week 4-1.3 ± 0.41-1.4 ± 0.42-1.2 ± 0.56-1.4 ± 0.49
Week 8-1.2 ± 0.37-1.4 ± 0.44-1.2 ± 0.52-1.4 ± 0.52
SecondaryChange in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point

Value at Week 2, Week 4, or Week 8 minus value at baseline

Time frame:
2 weeks, 4 weeks , and 8 weeks
Reported as:
Mean · Ratio
Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point
RatioCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-1.3 ± 0.71-1.6 ± 0.49-1.2 ± 0.61-1.5 ± 0.64
Week 4-1.4 ± 0.48-1.6 ± 0.49-1.4 ± 0.69-1.6 ± 0.59
Week 8-1.3 ± 0.43-1.5 ± 0.51-1.4 ± 0.65-1.5 ± 0.62
SecondaryChange in Apolipoprotein B From Baseline to Each Observation Point

Value at Week 2, Week 4, or Week 8 minus value at baseline

Time frame:
2 weeks, 4 weeks, and 8 weeks
Reported as:
Mean · mg/dL
Change in Apolipoprotein B From Baseline to Each Observation Point
mg/dLCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
Week 2-36.6 ± 12.55-45.8 ± 12.11-33.5 ± 9.86-44.4 ± 15.46
Week 4-40.1 ± 10.94-47.2 ± 10.20-36.6 ± 11.36-45.8 ± 13.79
Week 8-40.2 ± 9.65-46.4 ± 10.87-36.6 ± 12.27-45.1 ± 14.39

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CI-1038 2.5 mg/5 mg—0/43 (0%)6/43 (14%)
CI-1038 2.5 mg/10 mg—0/41 (0%)7/41 (17.1%)
CI-1038 5 mg/5 mg—0/41 (0%)8/41 (19.5%)
CI-1038 5 mg/10 mg—0/40 (0%)8/40 (20%)
Most frequent other events
Most frequent other events
EventCI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mg
NasopharyngitisInfections and infestations6/433/415/417/40
NauseaGastrointestinal disorders0/432/410/410/40
Seasonal AllergyImmune system disorders0/430/412/410/40
Pain in ExtremityMusculoskeletal and connective tissue disorders0/432/411/410/40
HeadacheNervous system disorders0/432/410/411/40

Baseline characteristics

Age, Customized
Age, Customized(participants)CI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mgTotal
<20 years00000
20 to 44 years834520
45 to 64 years2021232387
>=65 years1517141258
Sex: Female, Male
Sex: Female, Male(Participants)CI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mgTotal
Female2328252298
Male2013161867
Region of Enrollment
Region of Enrollment(participants)CI-1038 2.5 mg/5 mgCI-1038 2.5 mg/10 mgCI-1038 5 mg/5 mgCI-1038 5 mg/10 mgTotal
Japan43414140165
08

Study locations

17 sites
  • Pfizer Investigational Site
    Fukuoka-shi, Fukuoka-ken, Japan
  • Pfizer Investigational Site
    Kitakyushu-shi, Fukuoka-ken, Japan
  • Pfizer Investigational Site
    Kurume-shi, Fukuoka-ken, Japan
  • Pfizer Investigational Site
    Maebaru-shi, Fukuoka-ken, Japan
  • Pfizer Investigational Site
    Annaka, Gunma, Japan
  • Pfizer Investigational Site
    Sapporo-shi, Hokkaido, Japan
  • Pfizer Investigational Site
    Teine, Hokkaido, Japan
  • Pfizer Investigational Site
    Yokohama-shi, Kanagawa-ken, Japan
  • Pfizer Investigational Site
    Yamashita-cho, Naka-ku, Kanagawa-ken, Japan
  • Pfizer Investigational Site
    Kita-ku, Osaka-fu, Japan
  • Pfizer Investigational Site
    Koshigaya-shi, Saitama-ken, Japan
  • Pfizer Investigational Site
    Chofu, Tokyo, Japan
  • Pfizer Investigational Site
    Kiyose, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa, Tokyo, Japan
  • Pfizer Investigational Site
    Osaka, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2007
First posted
Sep 18, 2007
Start
Sep 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Apr 13, 2009
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00530946
Responsible party
Sponsor
First posted
Sep 18, 2007
Start date
Sep 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Apr 13, 2009
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion